Skip to main content

Advertisement

SpringerLink
Log in

Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Matrix metalloproteinases (MMPs) are a family of more than 28 enzymes that were initially identified on the basis of their ability to cleave most elements of the extracellular matrix (ECM) but have subsequently been found to be upregulated in nearly every tumor type. As digestion of the ECM is essential for tumor invasion and metastasis, MMPs have been studied for their role in these later stages of tumor development. More recently, exposure to these enzymes has been found to impact cellular signaling pathways that stimulate cell growth at early stages of tumor progression. MMPs have also been found to cleave intracellular targets and so inducing mitotic abnormalities and genomic instability. Emerging evidence indicates that tumor-associated MMPs can also stimulate processes associated with epithelial-mesenchymal transition (EMT), a developmental process that is activated in tumor cells during cell invasion and metastasis. Investigations of potential therapeutic MMP inhibitors aimed at blocking the protumorigenic tissue alterations induced by MMPs have been complicated by the side effects associated with nonspecific inhibition of normal physiological processes; recent investigations have shown how delineation of the extracellular targets and intracellular signaling pathways by which MMP action on cancer cells can induce EMT provides insight into novel therapeutic targets. Here, we provide an overview of recent findings of MMP action in tumors and the mechanisms by which MMPs induce both phenotypic and genotypic alterations that facilitate tumor progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Sieweke MH, Bissell MJ (1994) The tumor-promoting effect of wounding: a possible role for TGF-beta-induced stromal alterations. Crit Rev Oncog 5(2–3):297–311

    PubMed  CAS  Google Scholar 

  2. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516

    Article  PubMed  CAS  Google Scholar 

  3. Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1(1):46–54

    Article  PubMed  CAS  Google Scholar 

  4. Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7(2):131–142

    Article  PubMed  CAS  Google Scholar 

  5. Overall CM, Lopez-Otin C (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2(9):657–672

    Article  PubMed  CAS  Google Scholar 

  6. Matrisian LM (1994) Matrix metalloproteinase gene expression. Ann N Y Acad Sci 732:42–50

    Article  PubMed  CAS  Google Scholar 

  7. Westermarck J, Kahari VM (1999) Regulation of matrix metalloproteinase expression in tumor invasion. Faseb J 13(8):781–792

    PubMed  CAS  Google Scholar 

  8. Jones LE, Humphreys MJ, Campbell F et al (2004) Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 10(8):2832–2845

    Article  PubMed  CAS  Google Scholar 

  9. Liu D, Nakano J, Ishikawa S et al (2007) Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer. Lung Cancer 58(3):384–391

    Article  PubMed  Google Scholar 

  10. Morgia G, Falsaperla M, Malaponte G et al (2005) Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 33(1):44–50

    Article  PubMed  CAS  Google Scholar 

  11. Wu CY, Wu MS, Chiang EP et al (2007) Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 13(7):2054–2060

    Article  PubMed  CAS  Google Scholar 

  12. Mook OR, Frederiks WM, Van Noorden CJ (2004) The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705(2):69–89

    PubMed  CAS  Google Scholar 

  13. Somiari SB, Somiari RI, Heckman CM et al (2006) Circulating MMP2 and MMP9 in breast cancer—potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 119(6):1403–1411

    Article  PubMed  CAS  Google Scholar 

  14. Tetu B, Brisson J, Wang CS et al (2006) The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 8(3):R28

    Article  PubMed  Google Scholar 

  15. Yoshida H, Ishiko O, Sumi T et al (2001) Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int J Oncol 19(3):537–542

    PubMed  CAS  Google Scholar 

  16. Katayama A, Bandoh N, Kishibe K et al (2004) Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 10(2):634–640

    Article  PubMed  CAS  Google Scholar 

  17. Kerkela E, Saarialho-Kere U (2003) Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 12(2):109–125

    Article  PubMed  CAS  Google Scholar 

  18. Illman SA, Lehti K, Keski-Oja J et al (2006) Epilysin (MMP-28) induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells. J Cell Sci 119(Pt 18):3856–3865

    Article  PubMed  CAS  Google Scholar 

  19. Radisky DC, Levy DD, Littlepage LE et al (2005) Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436(7047):123–127

    Article  PubMed  CAS  Google Scholar 

  20. Lochter A, Sternlicht MD, Werb Z et al (1998) The significance of matrix metalloproteinases during early stages of tumor progression. Ann N Y Acad Sci 857:180–193

    Article  PubMed  CAS  Google Scholar 

  21. Noel A, Boulay A, Kebers F et al (2000) Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 19(12):1605–1612

    Article  PubMed  CAS  Google Scholar 

  22. McGuire JK, Li Q, Parks WC (2003) Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 162(6):1831–1843

    PubMed  CAS  Google Scholar 

  23. Song W, Jackson K, McGuire PG (2000) Degradation of type IV collagen by matrix metalloproteinases is an important step in the epithelial-mesenchymal transformation of the endocardial cushions. Dev Biol 227(2):606–617

    Article  PubMed  CAS  Google Scholar 

  24. Karsdal MA, Larsen L, Engsig MT et al (2002) Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem 277(46):44061–44067

    Article  PubMed  CAS  Google Scholar 

  25. Iida J, McCarthy JB (2007) Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-beta. Melanoma Res 17(4):205–213

    Article  PubMed  CAS  Google Scholar 

  26. Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14(2):163–176

    PubMed  Google Scholar 

  27. Yu WH, Woessner JF Jr, McNeish JD et al (2002) CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16(3):307–323

    Article  PubMed  CAS  Google Scholar 

  28. Cheng K, Xie G, Raufman JP (2007) Matrix metalloproteinase-7-catalyzed release of HB-EGF mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line. Biochem Pharmacol 73(7):1001–1012

    Article  PubMed  CAS  Google Scholar 

  29. Manes S, Llorente M, Lacalle RA et al (1999) The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 274(11):6935–6945

    Article  PubMed  CAS  Google Scholar 

  30. Shubayev VI, Myers RR (2000) Upregulation and interaction of TNFalpha and gelatinases A and B in painful peripheral nerve injury. Brain Res 855(1):83–89

    Article  PubMed  CAS  Google Scholar 

  31. Ito A, Mukaiyama A, Itoh Y et al (1996) Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem 271(25):14657–14660

    Article  PubMed  CAS  Google Scholar 

  32. Fishman DA, Bafetti LM, Stack MS (1996) Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis 16(3):150–159

    PubMed  CAS  Google Scholar 

  33. Du B, Wang P, Guo X et al (1999) Expression of membrane type 1-matrix metalloproteinase in laryngeal carcinoma. Pathol Oncol Res 5(3):214–217

    Article  PubMed  CAS  Google Scholar 

  34. Uchibori M, Nishida Y, Nagasaka T et al (2006) Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol 28(1):33–42

    PubMed  CAS  Google Scholar 

  35. Jiang WG, Davies G, Martin TA et al (2006) Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med 17(4):583–590

    PubMed  Google Scholar 

  36. Sounni NE, Noel A (2005) Membrane type-matrix metalloproteinases and tumor progression. Biochimie 87(3–4):329–342

    Article  PubMed  CAS  Google Scholar 

  37. Tam EM, Morrison CJ, Wu YI et al (2004) Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc Natl Acad Sci USA 101(18):6917–6922

    Article  PubMed  CAS  Google Scholar 

  38. Gilles C, Polette M, Seiki M et al (1997) Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest 76(5):651–660

    PubMed  CAS  Google Scholar 

  39. Ha HY, Moon HB, Nam MS et al (2001) Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Cancer Res 61(3):984–990

    PubMed  CAS  Google Scholar 

  40. Masson R, Lefebvre O, Noel A et al (1998) In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 140(6):1535–1541

    Article  PubMed  CAS  Google Scholar 

  41. Mudgett JS, Hutchinson NI, Chartrain NA et al (1998) Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum 41(1):110–121

    Article  PubMed  CAS  Google Scholar 

  42. Vu TH, Shipley JM, Bergers G et al (1998) MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93(3):411–422

    Article  PubMed  CAS  Google Scholar 

  43. Itoh T, Tanioka M, Matsuda H et al (1999) Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 17(2):177–181

    Article  PubMed  CAS  Google Scholar 

  44. Holmbeck K, Bianco P, Caterina J et al (1999) MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99(1):81–921

    Article  PubMed  CAS  Google Scholar 

  45. Wolf K, Wu YI, Liu Y et al (2007) Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol 9(8):893–904

    Article  PubMed  CAS  Google Scholar 

  46. Hotary KB, Allen ED, Brooks PC et al (2003) Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114(1):33–45

    Article  PubMed  CAS  Google Scholar 

  47. Nabeshima K, Inoue T, Shimao Y et al (2002) Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 52(4):255–264

    Article  PubMed  CAS  Google Scholar 

  48. Dumin JA, Dickeson SK, Stricker TP et al (2001) Pro-collagenase-1 (matrix metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen. J Biol Chem 276(31):29368–29374

    Article  PubMed  CAS  Google Scholar 

  49. Stefanidakis M, Ruohtula T, Borregaard N et al (2004) Intracellular and cell surface localization of a complex between alphaMbeta2 integrin and promatrix metalloproteinase-9 progelatinase in neutrophils. J Immunol 172(11):7060–7068

    PubMed  CAS  Google Scholar 

  50. Nisato RE, Hosseini G, Sirrenberg C et al (2005) Dissecting the role of matrix metalloproteinases (MMP) and integrin alpha(v)beta3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-type 1-MMP and alpha(v)beta3 are critical. Cancer Res 65(20):9377–9387

    Article  PubMed  CAS  Google Scholar 

  51. Thomas GJ, Lewis MP, Hart IR et al (2001) AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer 92(5):641–650

    Article  PubMed  CAS  Google Scholar 

  52. Hamidi S, Salo T, Kainulainen T et al (2000) Expression of alpha(v)beta6 integrin in oral leukoplakia. Br J Cancer 82(8):1433–1440

    PubMed  CAS  Google Scholar 

  53. Impola U, Uitto VJ, Hietanen J et al (2004) Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. J Pathol 202(1):14–22

    Article  PubMed  CAS  Google Scholar 

  54. Brooks PC, Stromblad S, Sanders LC et al (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85(5):683–693

    Article  PubMed  CAS  Google Scholar 

  55. Ellerbroek SM, Fishman DA, Kearns AS et al (1999) Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer Res 59(7):1635–1641

    PubMed  CAS  Google Scholar 

  56. Symowicz J, Adley BP, Gleason KJ et al (2007) Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res 67(5):2030–2039

    Article  PubMed  CAS  Google Scholar 

  57. Ratnikov BI, Rozanov DV, Postnova TI et al (2002) An alternative processing of integrin alpha(v) subunit in tumor cells by membrane type-1 matrix metalloproteinase. J Biol Chem 277(9):7377–7385

    Article  PubMed  CAS  Google Scholar 

  58. von Bredow DC, Nagle RB, Bowden GT et al (1997) Cleavage of beta 4 integrin by matrilysin. Exp Cell Res 236(1):341–345

    Article  Google Scholar 

  59. Murray D, Morrin M, McDonnell S (2004) Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism. Anticancer Res 24(2A):489–494

    PubMed  CAS  Google Scholar 

  60. Thanakit V, Sampatanukul P, Ruangvejvorachai P et al (2005) The association of co-expression of CD44v4/MMP-9 with different nodal status in high-grade breast carcinoma patients. J Med Assoc Thai 88(Suppl 4):S30–S35

    PubMed  Google Scholar 

  61. Gabison EE, Hoang-Xuan T, Mauviel A et al (2005) EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 87(3–4):361–368

    Article  PubMed  CAS  Google Scholar 

  62. Tang Y, Kesavan P, Nakada MT et al (2004) Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2(2):73–80

    PubMed  CAS  Google Scholar 

  63. Thomasset N, Lochter A, Sympson CJ et al (1998) Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. Am J Pathol 153(2):457–467

    PubMed  CAS  Google Scholar 

  64. Lochter A, Galosy S, Muschler J et al (1997) Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 139(7):1861–1872

    Article  PubMed  CAS  Google Scholar 

  65. Bergers G, Coussens LM (2000) Extrinsic regulators of epithelial tumor progression: metalloproteinases. Curr Opin Genet Dev 10(1):120–127

    Article  PubMed  CAS  Google Scholar 

  66. Lee KH, Choi EY, Hyun MS et al (2007) Association of extracellular cleavage of E-cadherin mediated by MMP-7 with HGF-induced in vitro invasion in human stomach cancer cells. Eur Surg Res 39(4):208–215

    Article  PubMed  CAS  Google Scholar 

  67. Covington MD, Burghardt RC, Parrish AR (2006) Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14). Am J Physiol Renal Physiol 290(1):F43–F51

    Article  PubMed  CAS  Google Scholar 

  68. Mei JM, Borchert GL, Donald SP et al (2002) Matrix metalloproteinase(s) mediate(s) NO-induced dissociation of beta-catenin from membrane bound E-cadherin and formation of nuclear beta-catenin/LEF-1 complex. Carcinogenesis 23(12):2119–2122

    Article  PubMed  CAS  Google Scholar 

  69. Golubkov VS, Strongin AY (2007) Proteolysis-driven oncogenesis. Cell Cycle 6(2):147–150

    PubMed  CAS  Google Scholar 

  70. Golubkov VS, Chekanov AV, Savinov AY et al (2006) Membrane type-1 matrix metalloproteinase confers aneuploidy and tumorigenicity on mammary epithelial cells. Cancer Res 66(21):10460–10465

    Article  PubMed  CAS  Google Scholar 

  71. Golubkov VS, Chekanov AV, Doxsey SJ et al (2005) Centrosomal pericentrin is a direct cleavage target of membrane type-1 matrix metalloproteinase in humans but not in mice: potential implications for tumorigenesis. J Biol Chem 280(51):42237–42241

    Article  PubMed  CAS  Google Scholar 

  72. Si-Tayeb K, Monvoisin A, Mazzocco C et al (2006) Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am J Pathol 169(4):1390–1401

    Article  PubMed  CAS  Google Scholar 

  73. Limb GA, Matter K, Murphy G et al (2005) Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am J Pathol 166(5):1555–1563

    PubMed  CAS  Google Scholar 

  74. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161–174

    Article  PubMed  CAS  Google Scholar 

  75. Sillanpaa S, Anttila M, Voutilainen K et al (2007) Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol 104(2):296–303

    Article  PubMed  CAS  Google Scholar 

  76. Zhang Q, Chen X, Zhou J et al (2006) CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther 5(7):808–814

    Article  PubMed  CAS  Google Scholar 

  77. Cardillo MR, Di Silverio F, Gentile V (2006) Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Anticancer Res 26(2A):973–982

    PubMed  CAS  Google Scholar 

  78. Ohtani H, Motohashi H, Sato H et al (1996) Dual over-expression pattern of membrane-type metalloproteinase-1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy. Int J Cancer 68(5):565–570

    Article  PubMed  CAS  Google Scholar 

  79. McCawley LJ, Crawford HC, King LE Jr et al (2004) A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res 64(19):6965–6972

    Article  PubMed  CAS  Google Scholar 

  80. Owen JL, Iragavarapu-Charyulu V, Gunja-Smith Z et al (2003) Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor. J Immunol 171(8):4340–4351

    PubMed  CAS  Google Scholar 

  81. Coussens LM, Tinkle CL, Hanahan D et al (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103(3):481–490

    Article  PubMed  CAS  Google Scholar 

  82. Tse JC, Kalluri R (2007) Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 101(4):816–829

    Article  PubMed  CAS  Google Scholar 

  83. Sternlicht MD, Lochter A, Sympson CJ et al (1999) The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 98(2):137–146

    Article  PubMed  CAS  Google Scholar 

  84. Sympson CJ, Bissell MJ, Werb Z (1995) Mammary gland tumor formation in transgenic mice overexpressing stromelysin-1. Semin Cancer Biol 6(3):159–163

    Article  PubMed  CAS  Google Scholar 

  85. Lochter A, Srebrow A, Sympson CJ et al (1997) Misregulation of stromelysin-1 expression in mouse mammary tumor cells accompanies acquisition of stromelysin-1-dependent invasive properties. J Biol Chem 272(8):5007–5015

    Article  PubMed  CAS  Google Scholar 

  86. Jordan P, Brazao R, Boavida MG et al (1999) Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene 18(48):6835–6839

    Article  PubMed  CAS  Google Scholar 

  87. Schnelzer A, Prechtel D, Knaus U et al (2000) Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 19(26):3013–3020

    Article  PubMed  CAS  Google Scholar 

  88. Singh A, Karnoub AE, Palmby TR et al (2004) Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene 23(58):9369–9380

    Article  PubMed  CAS  Google Scholar 

  89. Feig DI, Reid TM, Loeb LA (1994) Reactive oxygen species in tumorigenesis. Cancer Res 54(7 Suppl):1890s–1894s

    PubMed  CAS  Google Scholar 

  90. Dong R, Wang Q, He XL et al (2007) Role of nuclear factor kappa B and reactive oxygen species in the tumor necrosis factor-a-induced epithelial-mesenchymal transition of MCF-7 cells. Braz J Med Biol Res 40(8):1071–1078

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic Cancer Center, Jacksonville, FL, 32224, USA

    Lidiya S. Orlichenko & Derek C. Radisky

Authors
  1. Lidiya S. Orlichenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Derek C. Radisky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Derek C. Radisky.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Orlichenko, L.S., Radisky, D.C. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis 25, 593–600 (2008). https://doi.org/10.1007/s10585-008-9143-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-008-9143-9

Keywords

Search

Navigation